ARDS:NSD-Aridis Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.21

Change

+0.04 (+0.65)%

Market Cap

USD 0.07B

Volume

0.01M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.75 (-6.19%)

USD69.53B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.98 (-0.46%)

USD55.62B 20.48 15.19
REGN Regeneron Pharmaceuticals, Inc

-2.76 (-0.57%)

USD51.68B 15.90 12.28
BNTX BioNTech SE

-6.11 (-3.45%)

USD50.45B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.42 (+0.84%)

USD37.30B 54.77 36.21
BGNE BeiGene, Ltd

-4.85 (-1.56%)

USD29.11B N/A N/A
RPRX Royalty Pharma plc

-0.65 (-1.53%)

USD25.78B 22.60 15.82
SGEN Seagen Inc

-1.11 (-0.82%)

USD24.72B 38.00 35.77
GMAB Genmab A/S

+1.09 (+3.06%)

USD24.27B 26.59 3.52
CVAC CureVac N.V

-7.93 (-7.27%)

USD22.38B N/A N/A

ETFs Containing ARDS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.31% 59% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.31% 59% F 41% F
Trailing 12 Months  
Capital Gain -30.30% 23% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.30% 23% F 7% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.69% 22% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.69% 22% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 25.76% 92% A- 65% D
Risk Adjusted Return -37.60% 16% F 8% F
Market Capitalization 0.07B 12% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.83 62% D- 87% B+
Price/Book Ratio 5.40 45% F 32% F
Price / Cash Flow Ratio -3.47 26% F 64% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 1.03% 88% B+ 55% F
Return on Assets -64.99% 8% F 3% F
Debt to Equity Ratio -3.18% 89% B+ 93% A
Technical Ratios  
Short Ratio 0.46 89% B+ 82% B-
Short Percent 0.19% 99% A+ 94% A
Beta 0.11 93% A 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector